Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Raised 2026 revenue guidance to $410–$420 million on Amtagvi demand; shares gained about 47% over the 21 trading days through October 14 and closed near a period high. Losses and cash burn make this a high-risk momentum pick.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Margin Improvement • Strong Liquidity • Ongoing Cash Burn IOVA shows improving revenue, margins, liquidity, and leverage, but persistent losses, cash burn, dilution, and a high sales multiple make it a high-risk investment.
Price Behavior
Key Price Behavior Insights: • Strong uptrend • Accelerating momentum • Pullback risk Support Level: $9.25–$9.36; $8.60–$8.80 Resistance Level: $10.25 IOVA gained 24% over the last month to $10.25, but its RSI near 81 signals elevated pullback risk unless it decisively breaks above resistance.
Sentiment & News
Key News Insights: • Amtagvi sales growth • NSCLC data catalyst • Mixed institutional activity Iovance's surge reflects strong Amtagvi sales momentum and upcoming lung-cancer data catalysts, though mixed institutional trading signals warrant caution.
AI Summary
Iovance's investable shift is that Amtagvi's ~$100M quarterly revenue and 56% gross margin indicate a potentially scalable TIL commercial model, but after a sharp rerating investors should require sustained utilization-driven growth, lower cash burn, and strong lung-cancer data before adding exposure.
Description
Iovance Biotherapeutics is a clinical-stage biotechnology company that develops cell-based cancer immunotherapies using patients' own immune cells to target tumors. Its lead candidates, including lifileucel and LN-145, are being evaluated in multiple phase 2 trials for indications such as metastatic melanoma, cervical cancer and head and neck cancer. The company maintains collaborations and licensing arrangements with academic cancer centers and pharmaceutical partners, was founded in 2007, changed its name from Lion Biotechnologies in 2017, and is headquartered in San Carlos, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 14 | Oct 21 | IOVA | Iovance Biotherapeutics, Inc. | Raised 2026 revenue guidance to $410–$420 million on Amtagvi demand; shares gained about 47% over the 21 trading days through October 14 and closed near a period high. Losses and cash burn make this a high-risk momentum pick. | Closed | +2.9% |
| Oct 7 | Oct 14 | IOVA | Iovance Biotherapeutics, Inc. | Iovance raised 2026 revenue guidance to $410–$420 million after Q2 revenue grew 66% year over year. Shares gained about 52% over 21 trading days, making this a volatile commercial-growth opportunity. | Closed | +10.0% |
| Sep 29 | Oct 6 | IOVA | Iovance Biotherapeutics, Inc. | On September 29, Iovance raised its 2026 revenue-guidance midpoint by $55 million following strong Amtagvi demand. Shares reached a period high, but an 86% rise over 21 trading days makes reversal risk substantial. | Closed | -10.3% |
| Mar 10 | Mar 17 | IOVA | Iovance Biotherapeutics, Inc. | Event-driven oncology trade: recent positive AMTAGVI data (strong response and disease-control rates) and 50% ORR in a sarcoma pilot have driven a ~100% move off mid‑February lows, with earnings also beating on revenue and margins. With multiple upcoming TIL program updates and manufacturing transition milestones, IOVA remains a high-volatility name where additional clinical or commercialization news could trigger further short-term upside swings. | Closed | -25.2% |
| Feb 25 | Mar 4 | IOVA | Iovance Biotherapeutics, Inc. | Near‑term biotech momentum play: strong new clinical data (≈50–52% ORR, 73% disease control in lifileucel/Amtagvi programs) and a large gap‑up (~31% 21‑day gain, ~39% above 21‑day SMA) ahead of the 2026‑02‑24 Q4/webcast create a high‑volatility breakout with active newsflow and technical follow‑through potential over the next few days. | Closed | +11.2% |